<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617209</url>
  </required_header>
  <id_info>
    <org_study_id>21CH036</org_study_id>
    <nct_id>NCT05617209</nct_id>
  </id_info>
  <brief_title>In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients</brief_title>
  <official_title>Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have shown, in haemophilia patients, the effectiveness of Anti TFPI antibody&#xD;
      (aTFPIAb) to prevent joint and muscular bleeding (tissues poor in Tissue Factor (TF)).&#xD;
      However, cases of cerebral thrombosis (tissues rich in TF) have been observed in some&#xD;
      patients treated with this antibody. Because an inter-individual variation in thrombin&#xD;
      generation correction by aTFPIAb, an aTFPIAb concentration effective at low TF concentration&#xD;
      could be at the same time thrombogenic at high TF concentration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to determine, for each patient, the minimum concentration of aTFPIAb&#xD;
      necessary to restore thrombin generation in the presence of low (1pM) TF concentration and to&#xD;
      evaluate at this concentration of aTFPIAb a potential thrombogenic effect in the presence of&#xD;
      a high (10pM) TF concentration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>minimum concentration of anti-TFPI antibody</measure>
    <time_frame>day 1</time_frame>
    <description>Determine the minimum concentration of anti-TFPI antibody (µg/ml) that normalizes the peak to 1 pM FT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the clot structure</measure>
    <time_frame>day 1</time_frame>
    <description>Measurement of the clot structure (density fibers in g/cm3) by scanning electron microscopy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Severe and/or moderate haemophilia A and B</arm_group_label>
    <description>At the end of the consultation and follow-up of the disease, an additional blood sample of 35 ml (8 tubes) will be taken</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>thrombin generation measurement</intervention_name>
    <description>Thrombin generation will be measured in Platelets rich plasma induced either by 1 pM TF or 10 pM TF concentration in presence of different aTFPIAb concentrations (0; 0.5 µg/ml; 0.75 µg/ml; 1.0 µg/ml; 2.0 µg/ml; 4.0 µg/ml)</description>
    <arm_group_label>Severe and/or moderate haemophilia A and B</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling: thrombin generation measurement&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Haemophilia A and B patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe or moderate haemophilia A or B patient with FVIII or FIX &lt;5% with or without&#xD;
             prophylaxis&#xD;
&#xD;
          -  Affiliated or beneficiary of a social security regimen&#xD;
&#xD;
          -  Signature of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Haemophilia patients aged 12 years or less with a weight less than 30 kg (taking into&#xD;
             account the volume of blood collection).&#xD;
&#xD;
          -  Patients who received factor VIII concentrates less than 48 hours or factor IX&#xD;
             concentrates less than 96 hours prior to the routine blood draw at the Hemophilia&#xD;
             Clinic. 96 hours prior to the routine blood draw at the Hemophilia Centre&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte Tardy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Saint Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte Tardy-, MD</last_name>
    <phone>(0)477828591</phone>
    <phone_ext>+33</phone_ext>
    <email>brigitte.tardy@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>RANCON Florence, CRA</last_name>
    <phone>(0)477829458</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.rancon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte TARDY-PONCET, MD</last_name>
      <email>brigitte.tardy@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Tardy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>December 13, 2022</last_update_submitted>
  <last_update_submitted_qc>December 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-TFPI antibody</keyword>
  <keyword>thrombin generation</keyword>
  <keyword>tissue factor concentration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

